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BACKGROUND: The aim of this study was to assess the performance of the Revised Bethesda Guidelines (RBG) and the accuracy of the
Amsterdam II criteria (AM II) in identifying possible Lynch syndrome (LS) compared with the results of molecular tumour testing.
METHODS: Tumours from 336 unselected colorectal cancer patients were analysed by three molecular tests (namely microsatellite
instability (MSI), BRAF mutation and methylation of mismatch-repair genes), and patients were classified according to the RBG and
AM II criteria.
RESULTS: A total of 87 (25.9%) patients fulfilled the RBG for molecular tumour analyses (MSI and/or immunohistochemistry), and the
AM II identified 8 (2.4%) patients as having possible LS. Molecular tests identified 12 tumours (3.6%) as probable LS. The RBG
identified 6 of the 12 patients (sensitivity 50%), whereas 5 of the 8 patients who fulfilled the AM II criteria were not likely to be LS,
based on molecular tests (predictive value of positive test, 38%).
INTERPRETATION: Assuming a fairly high accuracy of molecular testing, the performance of the RBG in identifying patients with possible
LS was poor, and the AM II criteria falsely identified a large proportion as having possible LS. This favours the use of molecular testing
in the diagnosis of possible LS.
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Colorectal cancer (CRC) is the second most common cancer in
Norway, with B3500 new patients diagnosed annually in a
population of 4.7 million people (Cancer Registry of Norway;
http://www.kreftregisteret.no). It has been suggested that up to
20–25% of CRC cases are familial, including heredity caused by
identified genetic factors and familial clustering of CRC in which
the hereditary patterns are complex or unknown (de la Chapelle,
2004). Lynch syndrome (LS) constitutes 3–5% of all CRCs (Lynch
et al, 2004). In individuals with this autosomal dominant
predisposition, CRC tends to develop B20 years earlier than
sporadic CRC, and the lifetime risk for CRC is 50–80% (de la
Chapelle, 2004; Strate and Syngal, 2005). Patients with LS and
family members also have an increased risk of other LS-related
tumours (Tables 1 and 2) (de la Chapelle, 2004; Lynch et al, 2004).
In 1993, it was established that the underlying genetic causes of LS
were germline mutations in DNA mismatch-repair (MMR) genes
(de la Chapelle, 2004; Strate and Syngal, 2005).
The Amsterdam II criteria (AM II) (Table 1) are currently used
to identify patients with possible LS, whereas the Revised Bethesda
Guidelines 2004 (RBG) (Table 2) were developed to select CRC
patients for molecular tumour analyses (microsatellite instability
(MSI) and/or immunohistochemistry (ICH). If the results of these
molecular analyses indicate LS, it is recommended to carry out
germline testing of DNA MMR genes to confirm the diagnosis
(Vasen et al, 2007; Julie et al, 2008).
Approximately 95% of LS-associated tumours display a high
level of MSI (MSI-H), but 10–20% of sporadic CRCs are also
characterised by MSI (Young et al, 2001; Kambara et al, 2004), and
therefore, isolated MSI-H analyses cannot reliably identify LS-
related tumours. However, it has been shown that methylation of
MMR genes (such as MLH1, MSH2, MSH6 and PMS2)i sa n
underlying mechanism of sporadic MSI-H CRC, and methylation
status in combination with MSI could therefore be useful in
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sdiscriminating sporadic from LS-associated CRC (Young et al,
2001; Hitchins et al, 2007). Exceptionally, microsatellite stable
(MSS) tumours with no BRAF mutation and no methylation of
MMR genes may be LS associated (Julie et al, 2008), and caused by
the less penetrant MSH6 gene that is mutated in approximately
5–10% of LS tumours, whereas mutations of MLH1 and MSH2
account for approximately 90–95% of LS tumours (de la Chapelle,
2004). Mutation of the BRAF oncogene in tumour tissue nearly
excludes the possibility of LS (Deng et al, 2004; Koinuma et al,
2004).
Therefore, we supplemented MSI analyses with the BRAF
mutation and methylation analyses of MMR genes, and used a
combination of these three molecular tests to discriminate
colorectal tumours that are likely to be associated with LS from
tumours that are not likely to be associated with LS (Deng et al,
2004; Domingo et al, 2004; Koinuma et al, 2004; Vasen et al, 2007).
The aim of the study was to assess the performance of the RBG in
selecting MSI-H CRC tumours that in most cases are associated
with LS, and to assess the accuracy of the AM II in identifying
patients with possible LS tumours against the results of molecular
tests. The study was conducted among unselected CRC patients
from two hospitals in Norway (Tranø et al, 2009).
MATERIALS AND METHODS
From January 2007 to June 2008, 336 unselected and consecutively
admitted patients with newly diagnosed CRC were recruited from
two hospitals in Norway (Tranø et al, 2009). The female–male
ratio was 0.94, and the mean age at diagnosis was 70 years (range:
29–99 years).
Each patient was interviewed and all relevant data from their
medical records were collected. The interviews included a detailed
family history of CRC and LS-related tumours or of any other
cancer in the family, as described previously (Tranø et al, 2009).
Pedigrees were traced vertically and laterally as far as possible. If
patients reported family members with suspected CRC or
‘abdominal cancer’, or if cancer of internal genital organs was
reported in female relatives, the patients and their families were
classified as having a negative family history of CRC or other LS-
related tumours (Table 2). Only patients who felt confident about
their relatives’ medical histories were classified with a positive
family history. We did not search in cancer registers or relatives’
medical records for verification of the information obtained from
interviews. Data collected from medical records included history of
cancer, family history, age, gender and histopathological reports.
From all patients who underwent surgery or those who had a
biopsy, 354 malignant tumours in 336 patients were examined for
histological features reported to be associated with possible LS
(Young et al, 2001; Jenkins et al, 2007). A total of 14 (4.2%)
patients (Table 3) had synchronous cancers; 3 of them had more
than two tumours. All pathological examinations were conducted
by two experienced pathologists (Tranø et al, 2009) and if the
pathology reports documented in the medical records differed
from the conclusions of the study pathologists, we used the latter
conclusions. All elements of the RBG (Table 2) and the AM II
(Table 1) were assessed, and each patient was classified according
to both sets of clinical criteria.
Molecular tests (MSI, BRAF and methylation analyses) were
performed on 354 tumours obtained from 336 patients using
paraffin-embedded tumour specimens, and control DNA from
each patient was obtained from normal colorectal mucosa or from
peripheral blood. Patients with synchronous CRC were classified as
fulfilling the RBG if one of the tumours indicated possible LS
according to molecular tests. Tumours were classified as micro-
satellite unstable (MSI-H) if two or more of six microsatellite
markers showed instability, and as MSS if no more than one of the
markers showed instability. No tumours were classified as those
with low MSI in this study. The MSI status was based on six
recommended microsatellite markers: TGF-b-IIR, BAT25, BAT40,
D5S107, D5S406 and D13S153 (Boland et al, 1998; Hendriks et al,
2006). All tumours were also tested for mutation of the BRAF
oncogene V600E, and methylation analyses of MMR genes
associated with LS were also performed (in the study, only
methylation of the MLH1 gene was found). Using these molecular
test results, tumours were either classified as likely to be LS, or not
likely to be associated with LS. The molecular analyses and
Table 1 Criteria of the Revised Bethesda Guidelines (One of the criteria
is sufficient to select the patient/family for further molecular testing for
Lynch syndrome)
1. CRC diagnosed in a patient o50 years of age
2. Presence of synchronous, metachronous colorectal or other Lynch-related
tumours,
a regardless of age
3. CRC with MSI-H phenotype
b diagnosed in a patient aged o60 years
4. Patient with CRC and a first-degree relative with a Lynch syndrome-related
tumour, with one of the cancers diagnosed at age o50 years
5. Patient with CRC with two or more first- or second-degree relatives with
Lynch syndrome-related tumour, regardless of age
Abbreviations: CRC¼colorectal cancer; MSI-H¼microsatellite instability-high.
aLynch syndrome-related tumours: colorectal, endometrial, stomach, ovarian,
pancreas, ureter, renal pelvis, biliary tract and brain tumours, sebaceous gland
adenomas and keratoacanthomas, and carcinoma of the small bowel.
bLymfocyte-
infiltrating tumours, low grade or undifferentiated, Crohn’s-like lymphocyte infiltration,
the presence of mucin or signet cells in the tumours, and ‘cribiform growth pattern’.
Table 2 The Amsterdam II criteria for Lynch syndrome (All criteria must
be fulfilled)
At least three relatives with colorectal cancer (CRC) or Lynch syndrome-
associated cancer: cancer of the endometrium, small bowel, ureters and renal
pelvis
One relative should be a first-degree relative of the other two
At least two successive generations should be affected
At least one tumour should be diagnosed before the age of 50 years
FAP (familial adenomatous polyposis) should be excluded. Tumours should be
verified by histopathological examination.
Table 3 Study participants according to categories of the Revised
Bethesda Guidelines (Classified according to the ‘dominant’ criterion; that
is, one patient can fulfil more than one of the criteria)
Revised Bethesda Guidelines 2004
Number of
patients
Proportion
(%)
1. CRC diagnosed in a patient o50 years 20 23.0
2. Presence of metachronous, synchronous
colorectal or other Lynch-related
a tumours,
regardless of age
14 16.1
3. CRC with MSI-H phenotype
b diagnosed before
60 years of age
21 24.1
4. Patient with CRC and a first-degree relative
with a LS-related tumour, with one cancer
diagnosed before 50 years of age
12 13.8
5. Patient with CRC with two or more first- or
second-degree relatives with a LS-related
tumour, regardless of age
20 23.0
Total 336 100.0
Abbreviations: CRC¼colorectal cancer; LS¼Lynch syndrome; MSI-H¼
microsatellite instability-high.
aLynch syndrome-related tumours: colorectal,
endometrial, stomach, ovarian, pancreas, ureters, renal pelvis, biliary tract and brain
tumours, sebaceous gland adenomas and keratoacanthomas, and carcinoma of the
small bowel.
bLymfocyte-infiltrating tumours, low grade or undifferentiated, Crohn’s-
like lymphocyte infiltration, the presence of mucin or signet cells in the tumours, and
‘cribriform growth pattern’.
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slaboratory techniques have been described previously (Aaltonen
et al, 1998; Boland et al, 1998; Loukola et al, 2001), and a summary
table is provided in Appendix A. Non-LS-associated tumours are
likely to be sporadic in the majority of cases, but other genetic
factors not related to LS may be present.
To secure blinded interpretation, information obtained from
medical records or from interviews on family history, or in-
formation about fulfilment of clinical guidelines (RBG, AM II),
was not disclosed to the pathologists or to the molecular
geneticists who were responsible for histopathological interpreta-
tions and molecular tumour analyses. Similarly, molecular tumour
test results were not communicated to the clinician before
classification of patients according to RBG, except for the
histopathological features that are required for assessing patients
according to the third criterion of the RBG (Table 2). Using the
results of the three molecular tumour tests as the ‘gold standard’,
we estimated sensitivity, specificity and positive predictive values
(PPVs) for the RBG and the AM II criteria. Statistical analyses were
conducted using SPSS for Windows, version 14.0 (SPSS Inc.,
Chicago, IL, USA).
Written informed consent to carry out molecular tumour
analysis was obtained from 336 patients. Nine patients were
unable to consent or provide any relevant information because of
dementia, incapacity to understand the language, psychiatric
disease or critical illness, and hence were not eligible to participate.
Two invited patients refused to participate. The study was
approved by the Regional Committee for Ethics in medical
research and by the Norwegian Data Inspectorate.
RESULTS
A total of 12 (3.6%) tumours from 12 patients were highly
indicative of LS, based on molecular test results. These tumours
were MSI-H, and had no BRAF (V600E) mutations or methylation
of MMR genes. The remaining 324 (96.4%) tumours had molecular
combinations not likely to be indicative of LS. Patients’ demo-
graphics, family histories and tumour characteristics from the 12
patients whose tumours were identified as likely to be LS associated
according to the molecular methods are listed in Table 4.
Table 4 Patient demographics, family history and tumour characteristics of patients with MSI-H, no BRAF mutation and no MLH1 methylation colorectal cancers
ID
Age
(years) Gender Family history Tumour localisation
Histopatholgogy of
tumour
Synchrounous
cancer
Metachronous
cancer RBG
1 81 M 4 FDRs; 2 Bro:Abd(67,76)
13 SDRs (4 SDR no knowledge about
disease)
Right colon
(Transverse colon)
Medium differentiation
Muc:+ Sign:+ Lymf: ? ,Cro:+
No No Negative
2 69 F 9 FDRs Fa:CR(70);Mo:CR(67)
18 SDRs (2 MaUn:Abd (60,60)
Left
(Rectosigmoid tumour)
Medium differentiated
Muc: ?, Sign: ?, L¼ ?,Cro: ?
No No Negative
3 64 M 8 FDRs (Fa:CR(76); Mo:Ma(70)
11 SDRs (MaUn; MaAu; and MaGrandMa:
Ca(old)
Right
(Coecum)
Medium differentiated.
Muc:  ,Sign:  ,Lymf:  ,
Cro:  
No No Negative
47 2 F 1 3
FDRs(Si:Abd(75),Si:Pa(75),Bro:Abd(66)
16 SDRs(PatAu:Ma(72)
Rectal cancer Medium differentiated
Muc: +,Sign:  ,Lymf: +,Cro:+
No No Negative
5 87 M Single child. No children. No knowledge of
Pat family
1 FDR (father unknown)
3 SDR (no ca)
Right (Transverse colon) Medium differentiated
Muc: -,Sign:  ,Lymf:  ,Cro:  
No No Negative
6 75 M No children
4 FDRs (1 Bro P(85))
18 SDRs (no cancer)
Left (Sigmoid cancer) Low differentiated
Muc: +,Sign:  ,Lymf: +,Cro: ?
No No Negative
7 87 F Single child. No knowledge of father/Pat
family
5 FDRs (Da:EN(38) Mo;Br(72))
9 SDRs (no ca)
Right (Ascending colon) Low differentiated
Muc:  ,Sign:  ,Lymf: ?,Cro:  
No Metachronous
EN(47)
Positive:
2.Met LS-related cancer
4.1 FDR with LS-ass ca
o50
8 58 M No children Small size family and limited
knowledge
3 FDRs: (Fa:CR(46))
6 SDRs (MatGrandMa:’abd’(75),
PatAu: Br
Right (Coecum) Low differentiated
Muc: +,Sign:  ,Lymf: -,Cro: ?
No No Positive:
3.Histopath o60 years
4.1 FDR with CRCo50
95 5 M 5 F D R s ( 2 o50 years)
15 SDRs(Mat cousin: Br(45)and
lymf.ca(46)
Right (Transverse colon) Medium differentiated
Muc: +,Sign:  ,Lymf: ?,Cro: +
No No 3. Histopath o60 years
10 72 M 11 FDRs440 years (Si:CR(58),
Da:CR(38)
12 SDRs (no cancer)
Right and left (Liver
flexure, sigmoid)
Medium differentiated
Muc:  ,Sign:  ,Lymf: -,Cro: +
Yes (sigmoid) No 2. Synchronous CR
4. 1 FDR with CRCo50
11 48 M 5 FDRs450 years Mo;CR(54) Si:EN(55)
16 SDRs (no ca)
Right (Ascending colon) Medium differtiated
Muc: +,Sign: +,Lymf: ?,Cro:+
No No 1.o50 years
12 46 F 6 FDRs420 years (Si:UC(51),
Mo:UC(48), Fa;P(75)
5 SDRs (MatGrandMo:Ur (450)
Right (Transverse colon) Medium differentiated
Muc: -,Sign:  ,Lymf:  ,Cro: 
No No 1.o50 years
5:42 FDR or SDR with
LS-ass ca
Abbreviations: Abd¼abdomen or abdominal; Au¼aunt; Br¼brain tumour; Bro¼brother; Ca¼cancer of unknown origin; CR¼colorectal; Cro¼Crohn’s-like aggregation of
lymphocytes in tumour; Da¼daughter; EN¼endometrium; F¼female; Fa¼father; FDR¼first-degree relative (mother, father, siblings, children); GrandFa¼grandfather;
GrandMo¼grandmother; LS-ass ca¼Lynch syndrome-related cancer; Lu¼lung cancer; Lymf¼lymphocytic infiltration of tumour; M¼male; Ma¼breast cancer;
Mat¼maternal; Mo¼mother; Muc¼mucinous differentiation 450% of secreting tumour cells; P¼prostate; Pa¼pancreas; Pat¼paternal; SDR¼second-degree relative
(grandparents, aunts, uncles, grandchildren); Si¼sister; Sign¼signet cells; So¼son; UC¼uterine cervix; Un¼uncle; Ur¼ureter or cancer of the ureter/renal pelvis. Lynch
syndrome-related tumours¼colorectal, endometrium, cancer of the small bowel and ureter or renal pelvic cancer.
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sAmong all patients, 57 (17.0%) had MSI-H tumours and 279
(83.0%) had MSS tumours. There was no BRAF mutation in 280
(83.3%) tumours, and 260 (92.9%) of these tumours were MSS.
The BRAF mutation was detected in 58 (17.3%) tumours: 19
(32.8%) of these were MSS and 39 (67.2%) were MSI-H. In
45 (13.4%) tumours, MLH1 methylation was found, all of which
were MSI-H.
The combination of an MSS tumour without a BRAF mutation
and no methylation of the MLH1 gene was observed in 260
tumours, and 19 tumours had a combination of MSS with
BRAF mutation and no MLH1 methylation. A total of 45 MSI-H
tumours were classified as not being associated with LS because
they had MLH1 methylation; 39 of these tumours also had
BRAF mutation, whereas 6 had no BRAF mutation. The majority of
these 45 tumours were found in patients with no family history
of CRC, the patients were elderly (mean age: 74.3 years)
and the majority were women (62.2%). The tumours tended to
be right sided (84.4%), mucinous (55.6%) and with low-grade
differentiation (48.9%). The molecular test results are listed in
Table 5.
Among the 336 patients, 8 (2.4%) fulfilled the AM II criteria for
LS. Although the AM II identified five of the eight patients as
having possible LS, the tumours were not LS associated according
to molecular tests (PPV 38%). Only three of the eight AM II-
positive patients (sensitivity 25%) had molecular test results
suggesting LS (Table 6). Clinical characteristics, the results of
molecular tumour analyses and family history of patients fulfilling
the AM II criteria are listed in Table 7.
On the other hand, among 324 CRC patients who were not
classified as having LS by molecular tumour testing, the AM II
criteria classified 319 as not being associated with LS (specificity
98%).
A total of 87 (25.9%) patients (44 men and 43 women) were
selected by the RBG for further analysis of MSI or IHC with the
intention to identify LS. In all, 6 of the 12 patients whose tumours
were identified by molecular tumour test results fulfilled the RBG
(sensitivity 50%) (Table 6). Among 324 patients who were not
likely to have LS tumours according to molecular test results, 243
did not fulfil the RBG (specificity 75%).
DISCUSSION
In this prospective study of unselected and consecutively
diagnosed CRC patients, we assessed the performance of currently
used clinical guidelines (AM II and RBG) against three separate
molecular tumour tests (MSI, BRAF and MLH1 methylation
analyses) in the identification of possible LS. Half of the patients
whose tumours were highly suspicious of LS did not fulfil the RBG
(sensitivity 50%), and five of the eight patients who had possible
LS according to AM II were not LS, on the basis of the results of
molecular testing.
The low sensitivity of AM II could be expected from previous
research (Vasen et al, 2007; Julie et al, 2008). The moderate PPV
(38%) in detecting possible LS-associated tumours in this study
may question the usefulness of the AM II criteria in identifying LS
patients. Other studies have reported that molecular screening
analyses (MSI and IHC) may identify CRC patients as being
associated with LS, despite the failure of the AM II criteria to
identify these patients (Hampel et al, 2005). Furthermore, studies
have shown that the proportion of MMR gene mutations may
range from 49 to 80% among families who fulfil the AM II criteria
(Wijnen et al, 1997; Wagner et al, 2003).
The RBG were established to capture a high proportion of LS
patients by selecting tumours that should be tested for the
presence of MSI and/or IHC. Although not diagnostic, MSI is
strongly associated with LS. In that perspective, the RBG sensitivity
of 50% is disappointingly low. It is noteworthy that our estimate is
also low compared with other population-based studies that have
reported a sensitivity of B90% for RBG in identifying MSI-H
tumours suspicious of being LS associated (Pinol et al, 2005; Vasen
et al, 2007). Moreover, our results showed that only 7% of patients
who were selected for MSI/ICH testing by the RBG were confirmed
as being highly suspicious of LS by molecular tumour testing. Our
results suggest that the RBG may not be as useful as expected in
identifying patients who are eligible for further molecular tumour
analyses (MSI and/or ICH).
It could be argued that the low sensitivity of the RBG and
modest predictive values of the AM II suggest that the molecular
tests of this study may not represent a good diagnostic standard
for the detection of LS. However, it is well documented that B95%
of CRC tumours associated with LS are MSI-H (Boland, 2006).
Table 5 Comparison between the molecular test results and fulfilment of clinical guidelines
MSI status BRAF mutation MLH1 meth N¼336 RBG positive RBG negative AM II positive AM II negative
LS MSI-H Wt Neg 12 6 6 3 9
Non-LS MSI-H Wt Pos 6 1 5 0 6
MSI-H sporadic CRC likely MSI-H V600E Pos 39 11 28 0 39
Non-LS MSS Wt Neg 260 63 197 5 255
Non-LS (sporadic CRC likely) MSS V600E Neg 19 6 12 0 19
Total 336 87 249 8 328
Abbreviations: AM II neg¼Amsterdam II criteria not fulfilled; AM II pos¼Amsterdam II criteria fulfilled; CRC¼colorectal cancer; LS¼Lynch syndrome; MLH1 meth
neg¼absence of MLH1 methylation; MLH1 meth pos¼methylation of MLH1; MSI¼microsatellite instability; MSI-H¼microsatellite instable tumour; MSS¼microsatellite stable
tumour; non-LS¼CRC not associated with Lynch syndrome; RBG pos¼Revised Bethesda Guidelines fulfilled; RBG neg¼Revised Bethesda Guidelines not fulfilled;
V600E¼presence of the BRAF oncogene; Wt¼absence of the BRAF oncogene.
Table 6 Performance of the Revised Bethesda Guidelines (2004) and
accuracy of the Amsterdam II criteria against the molecular tumour analyses
Molecular tumour analyses
Lynch syndrome
likely
Lynch syndrome
not likely
Revised Bethesda Guidelines (RBG)
Positive 6 81 87
Negative 6 243 249
12 324 336
Amsterdam II criteria (AM II)
Positive 3 5 8
Negative 9 319 328
12 324 336
Abbreviations: CI¼confidence interval; PPV¼positive predictive value. RBG:
Sensitivity 50% (95% CI, 21–79%); specificity 75% (95% CI, 70–80%), PPV 7%
(95% CI, 3–14%). AM II: Sensitivity 25% (95% CI, 6–57%), specificity 98% (95% CI,
96–99%), PPV 38% (95% CI, 9–76%).
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sAlthough a small subgroup with MSH6 mutation may be MSS (Ku
et al, 1999), MSH6 mutations only account for o10% of MMR
mutation defects, whereas MLH1 and MSH2 mutations account for
more than 90% of MMR mutations in LS (Domingo et al, 2004). As
10–20% of sporadic CRC tumours are MSI-H, isolated MSI-H
status cannot reliably confirm LS. However, methylation of MMR
genes (mainly MLH1) strongly suggests that MSI-H tumours are
sporadic (Niv, 2007). Two studies have reported possible germline
methylations of MLH1 and MSH2 (Chan et al, 2006; Hitchins et al,
2007), but in one study, methylation could not be detected in other
family members, and was therefore not likely to be caused by
germline inheritance (Hitchins et al, 2007). Others have not been
able to verify germline MMR methylation (Boland et al, 2008).
Therefore, MLH1 methylation is presumed to reflect an epigenetic
mechanism that inactivates the MLH1 gene (and possibly the
MSH2 gene), causing MSI-H in tumours not associated with LS. If
BRAF V600E mutations are present in MSI-H tumours, the
possibility of LS can be nearly excluded, but only approximately
40–50% of MSI-H sporadic CRC tumours are reported to have
BRAF mutations (Wang et al, 2003). We therefore used a
combination of these three molecular tumour tests as an
alternative to germline mutation analyses to detect possible
LS-associated tumours in this study.
The molecular tumour characteristics of the patients in our
study seem to be as expected in an unselected group of CRC
patients, as the distribution of various molecular and genetic
variants is fairly similar to that observed in other population-based
studies (de la Chapelle, 2004; Hampel et al, 2005). BRAF mutations
are reported to be present in B15% of sporadic CRCs, which
compares with our result of 17.3%. It has been reported that a large
majority (43–87%) of MSI-H sporadic tumours have BRAF
mutations, whereas only a small proportion (4–9%) of MSS
tumours have BRAF mutations (Domingo et al, 2004; Kambara
et al, 2004). In our study, the respective proportions were 67.7%
(MSI-H) and 5.6% (MSS). Approximately 10–20% of sporadic
CRC tumours have been reported to be MSI-H (Imai and
Yamamoto, 2008), and the corresponding proportion in our study
was 17%. The prevalence of CRCs associated with LS has been
3–5% in most studies (de la Chapelle, 2004; Lynch et al, 2004;
Vasen et al, 2007), and on the basis of molecular tumour tests, we
estimated a prevalence of 3.6%. Most studies of unselected CRC
patients have analysed MLH1 and MSH2 genes, as these are most
commonly mutated in LS (de la Chapelle, 2004; Domingo et al,
2004; Julie et al, 2008). Pinol et al (2005) performed only IHC and
MSI analyses among unselected CRC patients to identify MSH2
and MLH1 germline mutation carriers, whereas we also included
molecular analyses for the detection of mutations of MSH6 and
PMS2. Many studies have used highly selected groups of CRC
patients, or included patients from hereditary cancer clinics
(Young et al, 2001; Hitchins et al, 2007) Differences in study
design will typically complicate comparisons with the results of
population studies.
Molecular tumour analyses may improve the diagnostic
accuracy of LS (Vasen et al, 2007; Julie et al, 2008), and several
molecular analyses have been used (Young et al, 2001; Deng et al,
2004; Kambara et al, 2004; Koinuma et al, 2004; Pinol et al, 2005;
Imai and Yamamoto, 2008). Immunohistochemistry has the
advantage of identifying the underlying MMR gene defect, and
germline analyses can be targeted to that specific MMR gene.
However, IHC can only identify loss of proteins due to known
Table 7 Clinical characteristics, molecular screening test results and family history of patients fulfilling the Amsterdam II criteria
ID
Age at
CRC
(years) Gender
Tumour
localisation MSI status BRAF
Methylation
status
Molecular
analyses
conclusion
Tumour in relative (age at
diagnosis in years)
Germline
test result
1 48 M Right colon MSI-H Wt Neg LS likely Mo:CR(54);
Si:EN(55)
PMS2
2 46 F Right colon MSI-H Wt Neg LS likely Mo:EN(48); MatGrandMo:Ur(56);
Fa:Pro(70) Si:CER(51);
MSH2
3 74 F Rectum MSS Wt Neg Likely non-LS Da:EN(48);Si:EN(49);
MatGrandFa:Abd(70)
4 75 F Right colon MSS Wt Neg Likely non-LS Mo:CR(46);
Bro:CR(78);Si:Cr(79)
5 67 M Right colon MSS Wt Neg Likely non-LS Bro:CR(35);Fa:Cr(85);
PatGrandPa:Cr(60);
PatUn:Abd(B70);
PatUn:Abd (B70);
PatAu:Abd(B70);
PatAu:Abd(B70)
6 59 M Rectum MSS Wt Neg Likely non-LS Bro:CR(29); Mo:EN(40);
MatAu:CR(58);MatAu:CR(63)
Fa:Pro(65);
11 MatAu/MatUn:Unkn
7 81 M Right colon MSS Wt Neg Likely non-LS Bro:CR(70);
Pat Un:CR(53);
Pat Un CR(27);
Pat Un:CR(50);
Fa: ‘Bile/gall bladder’;
Mat Un;Lung(smoker)
—
8 72 M Right and left
colon (synch)
MSI-H Wt Neg LS likely Si: CR(58).
Da: CR(38);
Pat.Un CR(53);
Pat.Un Abd(50)
Germline test
MLH1, MSH2,
MSH6, PMS2,
negative
Abbreviations: Abd¼abdomen; Au¼aunt; Bro¼brother; CR¼colorectal; CRC¼colorectal cancer; Da¼daughter; EN¼endometrium; Fa¼father; GrandFa¼grandfather;
GrandMo¼grandmother; Mat¼maternal; methylation status¼promotor methylation of MLH1; Mo¼mother; MSI¼microsatellite status; MSI-H¼microsatellite high;
MSS¼microsatellite stable; neg¼no methylation; Pat¼paternal; pos¼methylation found; Pro¼prostate; Si¼sister; So¼son; Un¼uncle; Unkn¼unknown; Ur¼ureter or
cancer of the ureter/renal pelvis; UT CER¼uterine cervix; wt¼no BRAF mutation. Molecular screening analyses conclusion:L S¼if possible LS; non-LS¼if likely sporadic CRC.
Lynch syndrome-associated tumours¼colorectal, endometrium, cancer of the small bowel and ureter or renal pelvic cancer.
Clinical guidelines in identifying LS
G Tranø et al
486
British Journal of Cancer (2010) 102(3), 482–488 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sMMR gene mutations, whereas MSI analyses can indicate other
potentially pathogenic MMR genes (Hampel et al, 2005; Hendriks
et al, 2006; Lynch et al, 2007; Zhang, 2008).
Ideally, the combination of the three molecular tumour tests that
we used should be validated against germline analyses. It is a
weakness of this study that the results of germline analyses were
not available. On the other hand, there are also weaknesses related
to the performance and interpretation of germline analyses (de la
Chapelle, 2004; Lynch et al, 2004), and the existence of other, not
yet detected, genetic causes of LS cannot be excluded.
The six microsatellite markers that we used have been validated
against MSI analyses, and have been found to perform well (Boland
et al, 1998; Young et al, 2001; Hampel et al, 2005). Some studies
have restricted the analysis to one marker (Pinol et al, 2005), and
others have used some of the markers that we used. The panel of
markers recommended by Boland et al (1998) has been used in
several studies.
A reliable family history is an important criterion, both for the
RBG and AM II (de la Chapelle, 2004; Lynch et al, 2004; Strate and
Syngal, 2005). Many studies have shown that the quality of family
history is suboptimal. This may be caused by patients’ lack of
knowledge about their family’s medical history, small-size families
and other factors, but also because the importance of family
history in CRC is often neglected by the clinician (Sanchez et al,
2008; Tranø et al, 2009). It is a strength of this study that the
investigators who obtained family history were blinded to the
results of the molecular tumour analyses and to pathology reports.
Nonetheless, family history could be misclassified and could
thereby influence the results of our study. Thus, if patients
systematically underreported family history, or if family history
was underestimated by the investigators, the sensitivity of the RBG
could be underestimated. Similarly, the PPV of the AM II could
also be underestimated. However, this potential bias was of great
concern, and every effort was made to record family history
accurately.
Age at diagnosis of the patient or of affected family members is
an essential criterion for LS (de la Chapelle, 2004; Lynch et al,
2004; Strate and Syngal, 2005). However, the importance of early
age at diagnosis seems to be less emphasised now than previously
(Lynch et al, 2004; Boland, 2006). Whether histopathological
features associated with LS are age dependent is not clear (Young
et al, 2001; Boland et al, 2008), and the age limit of 60 years at
diagnosis in the third criterion of the RBG may therefore be
questioned (Jenkins et al, 2007).
The identification of LS remains a challenge in the clinical
work up of CRC patients, and there is no single diagnostic test
available that can reliably identify patients with LS. In addition to
using clinical criteria, histopathological features and molecular
screening analyses could be incorporated in the assessment of all
CRC patients. Sanchez et al (2008) reported that the highest
detection rate of LS in CRC patients was obtained by the combined
efforts of the pathologist and the clinician.
CONCLUSIONS
In a series of unselected CRC patients, we assessed the
performance of the RBG and the accuracy of the AM II against
three molecular tumour tests that may fairly accurately detect LS.
The test combined MSI, BRAF mutation and MLH1 methylation
analyses.
The results showed that compared with molecular test results,
the clinical guidelines performed poorly in identifying possible LS-
associated tumours (RBG) or LS patients (AMII). The AM II
criteria identified a large proportion of tumours as LS that were
not associated with LS according to the molecular test results, and
the RBG failed to select 50% of patients whose tumours were likely
to be associated with LS.
Assuming that the molecular test results are fairly accurate,
these results suggest that screening of CRC tumours by these
molecular tumour tests could be offered to all CRC patients to
improve the diagnosis of LS.
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Appendix A
Laboratory methods:
Micro-dissection of paraffin-embedded tumour tissue and normal
mucosa and analyses for microsatellite instability (MSI) were
performed on matched pairs of tumour DNA and DNA from
normal mucosa or lymphocyte samples. DNA was extracted using
BioRobot EZ1 workstation from Qiagen (Hilden, Germany),
according to the manufacturer’s protocol (http://www.qiagen.
com).
Multiplex MSI analysis was performed comparing normal vs
tumour tissue at six microsatellite loci (TGF-b-IIR, BAT25, BAT40,
D5S107, D5S406 and D13S153) (Boland et al, 1998). If two or more
of the markers (30%) were shifted in size in tumour tissue, they
were classified as microsatellite unstable (MSI-High). (Aaltonen
et al, 1998; Loukola et al, 2001).
The BRAF mutation analysis was performed by screening for
a heteroduplex in exon 15. Subsequently DNA sequencing was
carried out to verify the p.Val600Glu mutation. Heteroduplex
analysis was performed by high-resolution melting (HRM) analysis
on the Rotor-Gene 6000 (Corbett Research, Mortlake, NSW,
Australia) machine. BRAF exon 15 primers were similar for HRM
and sequencing; forward primer TCATAATGCTTGCTCTGATAGGA
and reverse primer GGCCAAAAATTTAATCAGTGGA. In HRM
analyses, a 10ml PCR reaction was performed using master mix
Sensimix HRM Kit (Quantace, London, UK), with an annealing
temperature of 531C. Three parallels were analysed in the HRM
analyses with a melting temperature between 70 and 851C.
Methylation analyses were performed using the SALSA MS-MLPA
kit ME011 mismatch-repair genes according to the manufacturer’s
protocol (MRC-Holland, Amsterdam, The Netherlands) http://
www.mrc-holland.com).
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